Overview

ACY-7 Oral Administration of Acyline

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

We propose oral dosing of gastrointestinal permeation enhancement technology [GIPET] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four normal, healthy young men.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Merrion Pharmaceuticals, LLC

Treatments:

Acyline